B6E Stock Overview An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Swedish Orphan Biovitrum AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Swedish Orphan Biovitrum Historical stock prices Current Share Price SEK 26.86 52 Week High SEK 30.50 52 Week Low SEK 21.54 Beta 0.24 1 Month Change 6.67% 3 Month Change -4.95% 1 Year Change 12.67% 3 Year Change 48.15% 5 Year Change 81.61% Change since IPO 125.71%
Recent News & Updates
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28
Third quarter 2024 earnings released: EPS: kr4.27 (vs kr0.30 in 3Q 2023) Oct 24 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025 See more updates
Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors Dec 11
Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28
Third quarter 2024 earnings released: EPS: kr4.27 (vs kr0.30 in 3Q 2023) Oct 24 Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025 Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025
General Counsel & Head of Legal Affairs recently sold €2.4m worth of stock Sep 02
Investor sentiment improves as stock rises 16% Aug 20
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08
CEO & President recently sold €2.5m worth of stock Jul 29
Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct Jul 19
Second quarter 2024 earnings released: EPS: kr0.66 (vs kr0.71 in 2Q 2023) Jul 17 Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024 Jul 16
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout Jul 02
European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A Jun 20
Head of North America recently sold €3.3m worth of stock Jun 10
CEO & President recently sold €2.6m worth of stock Jun 03
Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member May 15
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024 Apr 28 Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025
Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022) Apr 03
Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024 Feb 29
Head of Technical Operations recently sold €501k worth of stock Feb 15
Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022) Feb 09
Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member Jan 05
Senior Scientific & Medical Advisor recently sold €1.4m worth of stock Nov 17
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024 Oct 31
Third quarter 2023 earnings released: EPS: kr0.30 (vs kr1.52 in 3Q 2022) Oct 31
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G Oct 18
Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer Oct 05 Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A Sep 25
Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion. Sep 20
Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024
New major risk - Financial position Jul 19
Second quarter 2023 earnings released: EPS: kr0.75 (vs kr0.87 in 2Q 2022) Jul 19
Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders. Jun 27
European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A May 19
Independent Chairman recently bought €1.0m worth of stock May 17
Less than half of directors are independent May 14 Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion. May 11
Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board May 10
Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021) Apr 08
Insider recently sold €1.2m worth of stock Mar 09
Head of Europe recently sold €1.4m worth of stock Mar 01
CEO & President recently sold €2.2m worth of stock Feb 17
Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021) Feb 09
Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023 Feb 08
Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes Feb 03
ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine) Dec 21
Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia Nov 11
Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023 Nov 01 Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023
Third quarter 2022 earnings released: EPS: kr1.52 (vs kr1.60 in 3Q 2021) Oct 28
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Sep 17
Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa Aug 30
Second quarter 2022 earnings released: EPS: kr0.87 (vs kr0.91 in 2Q 2021) Jul 20
Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022 Jul 20
Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress Jun 10
Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need Jun 08
FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi Jun 01
Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member May 12
First quarter 2022 earnings released: EPS: kr1.84 (vs kr2.36 in 1Q 2021) May 01
Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study Mar 10
Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH) Feb 26
Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022 Feb 01
Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia Dec 18 Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population Dec 15
Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others. Dec 05
Investor sentiment deteriorated over the past week Dec 04
Head of Technical Operations recently bought €134k worth of stock Nov 23
Third quarter 2021 earnings released: EPS kr1.60 (vs kr0.94 in 3Q 2020) Oct 23
Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia Sep 08
Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia Sep 04
Investor sentiment improved over the past week Sep 03
Orphan Biovitrum Jumps After Bloomberg Report of Potential Takeover Aug 27
Second quarter 2021 earnings released: EPS kr0.91 (vs kr0.96 in 2Q 2020) Jul 22
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH May 26
CEO & President recently bought €805k worth of stock May 26
Swedish Orphan Biovitrum AB (publ) Announces Early Use of Anakinra Reduces Risk of Mortality for Patients with Covid-19 Pneumonia, Reduces ICU Admission and Increases Likelihood of Full Recovery May 21
CEO & President recently bought €419k worth of stock May 13
Director has left the company May 11 Shareholder Returns B6E DE Biotechs DE Market 7D -3.2% -3.5% -2.0% 1Y 12.7% -14.7% 6.9%
See full shareholder returns
Return vs Market: B6E exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is B6E's price volatile compared to industry and market? B6E volatility B6E Average Weekly Movement 5.2% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: B6E has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: B6E's weekly volatility (5%) has been stable over the past year.
About the Company Founded Employees CEO Website 1939 1,814 Guido Oelkers www.sobi.com
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Show more Swedish Orphan Biovitrum AB (publ) Fundamentals Summary How do Swedish Orphan Biovitrum's earnings and revenue compare to its market cap? B6E fundamental statistics Market cap €9.29b Earnings (TTM ) €305.68m Revenue (TTM ) €2.21b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) B6E income statement (TTM ) Revenue SEK 25.44b Cost of Revenue SEK 5.44b Gross Profit SEK 19.99b Other Expenses SEK 16.48b Earnings SEK 3.51b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
Earnings per share (EPS) 10.23 Gross Margin 78.60% Net Profit Margin 13.82% Debt/Equity Ratio 47.1%
How did B6E perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 03:22 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alexander Lindström ABG Sundal Collier Rosie Turner Barclays Brian Balchin Barclays
Show 26 more analysts 
